These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 29871885)

  • 1. PD-L1 Binds to B7-1 Only
    Chaudhri A; Xiao Y; Klee AN; Wang X; Zhu B; Freeman GJ
    Cancer Immunol Res; 2018 Aug; 6(8):921-929. PubMed ID: 29871885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
    Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
    Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
    Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex.
    Garrett-Thomson SC; Massimi A; Fedorov EV; Bonanno JB; Scandiuzzi L; Hillerich B; Seidel RD; Love JD; Garforth SJ; Guha C; Almo SC
    PLoS One; 2020; 15(6):e0233578. PubMed ID: 32497097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restriction of PD-1 function by
    Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
    Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New expression of PD-L1 on activated CD4
    Mazerolles F
    Hum Immunol; 2024 Jul; 85(4):110831. PubMed ID: 38870593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction.
    Robinson MA; Kennedy A; Orozco CT; Chen HC; Waters E; Giovacchini D; Yeung K; Filer L; Hinze C; Lloyd C; Dovedi SJ; Sansom DM
    Cell Rep; 2024 Sep; 43(9):114768. PubMed ID: 39277860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of human PD-L1 and B7-1.
    Butte MJ; Peña-Cruz V; Kim MJ; Freeman GJ; Sharpe AH
    Mol Immunol; 2008 Aug; 45(13):3567-72. PubMed ID: 18585785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
    Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
    Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80.
    Kennedy A; Robinson MA; Hinze C; Waters E; Williams C; Halliday N; Dovedi S; Sansom DM
    EMBO J; 2023 Mar; 42(5):e111556. PubMed ID: 36727298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.
    Nishimura CD; Pulanco MC; Cui W; Lu L; Zang X
    Trends Mol Med; 2021 Mar; 27(3):207-219. PubMed ID: 33199209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells.
    Su Z; Dhusia K; Wu Y
    PLoS Comput Biol; 2021 Mar; 17(3):e1008825. PubMed ID: 33684103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80.
    Kang-Pettinger T; Walker K; Brown R; Cowan R; Wright H; Baravalle R; Waters LC; Muskett FW; Bowler MW; Sawmynaden K; Coombs PJ; Carr MD; Hall G
    J Biol Chem; 2023 Jan; 299(1):102769. PubMed ID: 36470427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.
    Zhang Y; Song Q; Cassady K; Lee M; Tang H; Zheng M; Wang B; Schones DE; Fu YX; Riggs AD; Martin PJ; Feng R; Zeng D
    Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2205085120. PubMed ID: 37036990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
    Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
    Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
    Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.